Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 3/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522278 | 1.00 | CTSL (0.35) | CTSLHTR1DHTR1BP2RX3IDH1 | |
| SCHEMBL4514233 | 0.91 | CTSL (0.36) | CTSLP2RX3IDH1 | |
| SCHEMBL4514235 | 0.91 | CTSL (0.36) | CTSLP2RX3IDH1 | |
| SCHEMBL13763361 | 0.90 | CTSL (0.34) | CTSLHTR1DHTR1BIDH1GRM2 | |
| SCHEMBL4518034 | 0.90 | HTR1D (0.35) | CTSLHTR1DHTR1BP2RX3IDH1 | |
| SCHEMBL4518032 | 0.90 | HTR1D (0.35) | CTSLHTR1DHTR1BP2RX3IDH1 | |
| SCHEMBL4521525 | 0.84 | LTA4H (0.35) | HTR1DHTR1BIDH1 | |
| SCHEMBL5331286 | 0.84 | LTA4H (0.35) | HTR1DHTR1BIDH1 | |
| SCHEMBL4236486 | 0.83 | P2RX3 (0.33) | CTSLP2RX3 | |
| SCHEMBL13757308 | 0.82 | PPARG (0.37) | HTR1DHTR1BIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | claimed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | CYP3A4, CYP4B1, CYP3A5 | CTSL 4355/4885HTR1D 562/4885HTR1B 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.